These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10646635)

  • 1. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors.
    Ren-Heidenreich L; Hayman GT; Trevor KT
    Hum Gene Ther; 2000 Jan; 11(1):9-19. PubMed ID: 10646635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.
    Daly T; Royal RE; Kershaw MH; Treisman J; Wang G; Li W; Herlyn D; Eshhar Z; Hwu P
    Cancer Gene Ther; 2000 Feb; 7(2):284-91. PubMed ID: 10770638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis.
    Ren-Heidenreich L; Mordini R; Hayman GT; Siebenlist R; LeFever A
    Cancer Immunol Immunother; 2002 Oct; 51(8):417-23. PubMed ID: 12202902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D; Groner B
    Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
    Cheung NK; Guo HF; Modak S; Cheung IY
    Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy.
    Teng MW; Kershaw MH; Jackson JT; Smyth MJ; Darcy PK
    Hum Gene Ther; 2006 Nov; 17(11):1134-43. PubMed ID: 17052145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
    Kobold S; Steffen J; Chaloupka M; Grassmann S; Henkel J; Castoldi R; Zeng Y; Chmielewski M; Schmollinger JC; Schnurr M; Rothenfußer S; Schendel DJ; Abken H; Sustmann C; Niederfellner G; Klein C; Bourquin C; Endres S
    J Natl Cancer Inst; 2015 Jan; 107(1):364. PubMed ID: 25424197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes.
    Rossig C; Bollard CM; Nuchtern JG; Merchant DA; Brenner MK
    Int J Cancer; 2001 Oct; 94(2):228-36. PubMed ID: 11668503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.
    Hombach A; Schneider C; Sent D; Koch D; Willemsen RA; Diehl V; Kruis W; Bolhuis RL; Pohl C; Abken H
    Int J Cancer; 2000 Oct; 88(1):115-20. PubMed ID: 10962448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
    Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
    Matsumoto H; Liao S; Arakawa F; Ueno A; Abe H; Awasthi A; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(4):2001-7. PubMed ID: 12174877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.
    Willuda J; Honegger A; Waibel R; Schubiger PA; Stahel R; Zangemeister-Wittke U; Plückthun A
    Cancer Res; 1999 Nov; 59(22):5758-67. PubMed ID: 10582696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor.
    Gyobu H; Tsuji T; Suzuki Y; Ohkuri T; Chamoto K; Kuroki M; Miyoshi H; Kawarada Y; Katoh H; Takeshima T; Nishimura T
    Cancer Res; 2004 Feb; 64(4):1490-5. PubMed ID: 14973062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U; Klundt E; Groner B
    J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model.
    Kroesen BJ; Helfrich W; Bakker A; Wubbena AS; Bakker H; Kal HB; The TH; de Leij L
    Int J Cancer; 1995 Jun; 61(6):812-8. PubMed ID: 7790116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.